UPDATE: Jefferies Lowers PT on AbbVie on Attractive Entry Point Potential
In a report published Friday, Jefferies analyst Jeffrey Holford reiterated a Buy rating on AbbVie (NYSE: ABBV), but lowered the price target from $54.00 to $51.00.
In the report, Jefferies noted, “We reiterate Novartis as our Top European and Global Pick with positive growth inflection potential in 2014 and significant restructuring optionality being key drivers. Abbott is our Top US Pick for similar reasons. We highlight Roche, Sanofi and AbbVie as potentially offering particularly attractive entry points following the recent sell-off. AstraZeneca is now our Least Preferred stock.”
AbbVie closed on Thursday at $43.04.
Latest Ratings for ABBV
|Apr 2016||Societe Generale||Initiates Coverage on||Sell|
|Mar 2016||Deutsche Bank||Initiates Coverage on||Hold|
|Mar 2016||Goldman Sachs||Downgrades||Conviction Buy||Buy|
© 2016 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.